Last 12 months
Inside the activity.
6 purchase rows · 47 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 1 |
| Dec 2025 | 1 | 34 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 6 |
| Mar 2026 | 4 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 4 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2021 Filed Feb 18, 2021 19:26 UTC |
Francis ChrisSee Remarks
|
GrantShare Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $10.48 | $0.00 |
DisclosureSEC source: 0000899243-21-007209 · doc4.xml · derivative · entry 3 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Ordinary Shares · 50,000 shares Expires 2031-02-01 F4 · derivative.exercise_date: The option vests as to 50% of the shares on February 15, 2022 and 50% on February 15, 2023. Read SEC document |
| February 01, 2021 Filed Feb 18, 2021 19:26 UTC |
Francis ChrisSee Remarks
|
GrantOrdinary Shares | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007209 · doc4.xml · nonDerivative · entry 1 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,160 F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in two equal installments on February 15, 2022 and February 15, 2023. Read SEC document |
| February 01, 2021 Filed Feb 19, 2021 00:18 UTC |
BOLNO PAULDirector · President and CEO
|
GrantShare Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $10.48 | $0.00 |
DisclosureSEC source: 0000899243-21-007207 · doc4.xml · derivative · entry 3 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Ordinary Shares · 200,000 shares Expires 2031-02-01 F4 · derivative.exercise_date: The option vests as to 50% of the shares on February 15, 2022 and 50% on February 15, 2023. Read SEC document |
| February 01, 2021 Filed Feb 19, 2021 00:18 UTC |
BOLNO PAULDirector · President and CEO
|
GrantOrdinary Shares | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007207 · doc4.xml · nonDerivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422,181 F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in two equal installments on February 15, 2022 and February 15, 2023. Read SEC document |
| February 01, 2021 Filed Feb 19, 2021 00:16 UTC |
Panzara Michael A.See Remarks
|
GrantShare Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $10.48 | $0.00 |
DisclosureSEC source: 0000899243-21-007206 · doc4.xml · derivative · entry 3 Panzara Michael A. · CIK 0001679039 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Ordinary Shares · 50,000 shares Expires 2031-02-01 F4 · derivative.exercise_date: The option vests as to 50% of the shares on February 15, 2022 and 50% on February 15, 2023. Read SEC document |
| February 01, 2021 Filed Feb 19, 2021 00:16 UTC |
Panzara Michael A.See Remarks
|
GrantOrdinary Shares | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007206 · doc4.xml · nonDerivative · entry 1 Panzara Michael A. · CIK 0001679039 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,349 F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in two equal installments on February 15, 2022 and February 15, 2023. Read SEC document |
| February 01, 2021 Filed Feb 19, 2021 00:09 UTC |
Moran KyleChief Financial Officer
|
GrantShare Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $10.48 | $0.00 |
DisclosureSEC source: 0000899243-21-007201 · doc4.xml · derivative · entry 3 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Ordinary Shares · 50,000 shares Expires 2031-02-01 F5 · derivative.exercise_date: The option vests as to 50% of the shares on February 15, 2022 and 50% on February 15, 2023. Read SEC document |
| February 01, 2021 Filed Feb 19, 2021 00:09 UTC |
Moran KyleChief Financial Officer
|
GrantOrdinary Shares | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007201 · doc4.xml · nonDerivative · entry 1 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,584 F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in two equal installments on February 15, 2022 and February 15, 2023. F2 · balance_after: Includes 1,500 ordinary shares acquired under the issuer's 2019 Employee Share Purchase Plan (ESPP) on January 14, 2021. Read SEC document |
| September 15, 2020 Filed Sep 18, 2020 01:10 UTC |
BOLNO PAULDirector · President and CEO
|
Exercise / conversionShare Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-20-025614 · doc4.xml · derivative · entry 3 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,778 Underlying: Ordinary Shares · 100,000 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: These share options are fully vested. Read SEC document |
| September 15, 2020 Filed Sep 18, 2020 01:10 UTC |
BOLNO PAULDirector · President and CEO
|
SaleOrdinary Shares | 100,000 | $15.00 | $1,500,000.00 |
DisclosureSEC source: 0000899243-20-025614 · doc4.xml · nonDerivative · entry 2 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,181 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 15, 2020 Filed Sep 18, 2020 01:10 UTC |
BOLNO PAULDirector · President and CEO
|
Exercise / conversionOrdinary Shares | 100,000 | $2.48 | $248,000.00 |
DisclosureSEC source: 0000899243-20-025614 · doc4.xml · nonDerivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 372,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 22:44 UTC |
BOLNO PAULDirector · President and CEO
|
Exercise / conversionShare Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-20-023540 · doc4.xml · derivative · entry 3 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,778 Underlying: Ordinary Shares · 25,000 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: These share options are fully vested. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 22:44 UTC |
BOLNO PAULDirector · President and CEO
|
SaleOrdinary Shares | 25,000 | $12.00 | $300,000.00 |
DisclosureSEC source: 0000899243-20-023540 · doc4.xml · nonDerivative · entry 2 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,181 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 22:44 UTC |
BOLNO PAULDirector · President and CEO
|
Exercise / conversionOrdinary Shares | 25,000 | $2.48 | $62,000.00 |
DisclosureSEC source: 0000899243-20-023540 · doc4.xml · nonDerivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:28 UTC |
HENRY CHRISTIAN ODirector
|
GrantShare Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0000899243-20-023078 · doc4.xml · derivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Ordinary Shares · 10,500 shares Expires 2025-08-18 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2021 annual general meeting or August 18, 2021. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 18:37 UTC |
CORRIGAN MARKDirector
|
GrantShare Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0000899243-20-023093 · doc4.xml · derivative · entry 1 CORRIGAN MARK · CIK 0001250661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Ordinary Shares · 10,500 shares Expires 2025-08-18 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2021 annual general meeting or August 18, 2021. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:37 UTC |
Kolchinsky PeterDirector · 10% owner
|
GrantShare Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0000899243-20-023092 · doc4.xml · derivative · entry 1 Kolchinsky Peter · CIK 0001384859 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Ordinary Shares · 10,500 shares Expires 2025-08-18 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2021 annual general meeting or August 18, 2021. F2 · ownership.direct: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:32 UTC |
Rawcliffe AdrianDirector
|
GrantShare Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0000899243-20-023085 · doc4.xml · derivative · entry 1 Rawcliffe Adrian · CIK 0001555851 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Ordinary Shares · 10,500 shares Expires 2025-08-18 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2021 annual general meeting or August 18, 2021. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 18:34 UTC |
Verdine Gregory L.Director
|
GrantShare Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0000899243-20-023089 · doc4.xml · derivative · entry 1 Verdine Gregory L. · CIK 0001572315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Ordinary Shares · 10,500 shares Expires 2025-08-18 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2021 annual general meeting or August 18, 2021. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:33 UTC |
Wagner Heidi LDirector
|
GrantShare Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0000899243-20-023088 · doc4.xml · derivative · entry 1 Wagner Heidi L · CIK 0001655029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Ordinary Shares · 10,500 shares Expires 2025-08-18 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2021 annual general meeting or August 18, 2021. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:33 UTC |
TAKANASHI KENDirector · 10% owner
|
GrantShare Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0000899243-20-023087 · doc4.xml · derivative · entry 1 TAKANASHI KEN · CIK 0001657768 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Ordinary Shares · 10,500 shares Expires 2025-08-18 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2021 annual general meeting or August 18, 2021. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:32 UTC |
Pott AmyDirector
|
GrantShare Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0000899243-20-023086 · doc4.xml · derivative · entry 1 Pott Amy · CIK 0001787363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Ordinary Shares · 10,500 shares Expires 2025-08-18 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2021 annual general meeting or August 18, 2021. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:30 UTC |
Tan Aik NaDirector
|
GrantShare Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0000899243-20-023080 · doc4.xml · derivative · entry 1 Tan Aik Na · CIK 0001821285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Ordinary Shares · 21,000 shares Expires 2025-08-18 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 25% of the shares on August 18, 2021 and the remainder vests quarterly thereafter until August 18, 2024. Read SEC document |
| July 02, 2020 Filed Jul 3, 2020 00:56 UTC |
BOLNO PAULDirector · President and CEO
|
Exercise / conversionShare Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-20-018398 · doc4.xml · derivative · entry 6 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,778 Underlying: Ordinary Shares · 100,000 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · derivative.exercise_date: These share options are fully vested. Read SEC document |
| July 02, 2020 Filed Jul 3, 2020 00:56 UTC |
BOLNO PAULDirector · President and CEO
|
SaleOrdinary Shares | 95,921 | $10.27 | $985,108.67 |
DisclosureSEC source: 0000899243-20-018398 · doc4.xml · nonDerivative · entry 5 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,181 F4 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $9.77 to $10.77 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 02, 2020 Filed Jul 3, 2020 00:56 UTC |
BOLNO PAULDirector · President and CEO
|
SaleOrdinary Shares | 4,079 | $10.91 | $44,501.89 |
DisclosureSEC source: 0000899243-20-018398 · doc4.xml · nonDerivative · entry 4 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,102 F4 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $10.78 to $11.12 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 02, 2020 Filed Jul 3, 2020 00:56 UTC |
BOLNO PAULDirector · President and CEO
|
Exercise / conversionOrdinary Shares | 100,000 | $2.48 | $248,000.00 |
DisclosureSEC source: 0000899243-20-018398 · doc4.xml · nonDerivative · entry 3 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 372,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 02, 2020 Filed Jul 3, 2020 00:56 UTC |
BOLNO PAULDirector · President and CEO
|
SaleOrdinary Shares | 43,068 | $10.26 | $441,877.68 |
DisclosureSEC source: 0000899243-20-018398 · doc4.xml · nonDerivative · entry 2 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,181 F1 · kind: Consists of the sale of shares that were issued upon the vesting of restricted share units. The sale was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $9.77 to $10.77 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 02, 2020 Filed Jul 3, 2020 00:56 UTC |
BOLNO PAULDirector · President and CEO
|
SaleOrdinary Shares | 4,509 | $10.82 | $48,787.38 |
DisclosureSEC source: 0000899243-20-018398 · doc4.xml · nonDerivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,249 F1 · kind: Consists of the sale of shares that were issued upon the vesting of restricted share units. The sale was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $10.78 to $11.12 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 20:48 UTC |
Gaiero David GInterim CFO
|
GrantShare Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $8.17 | $0.00 |
DisclosureSEC source: 0000899243-20-007284 · doc4.xml · derivative · entry 1 Gaiero David G · CIK 0001799784 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Ordinary Shares · 18,000 shares Expires 2030-03-03 F1 · derivative.exercise_date: The option vests as to 50% of the shares on February 1, 2021 and 50% on February 1, 2022. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 20:49 UTC |
Vargeese ChandraSenior VP, Drug Discovery
|
GrantShare Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $8.17 | $0.00 |
DisclosureSEC source: 0000899243-20-007285 · doc4.xml · derivative · entry 1 Vargeese Chandra · CIK 0001657675 · Senior VP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Ordinary Shares · 36,000 shares Expires 2030-03-03 F1 · derivative.exercise_date: The option vests as to 50% of the shares on February 1, 2021 and 50% on February 1, 2022. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 20:42 UTC |
Francis ChrisSee Remarks
|
GrantShare Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $8.17 | $0.00 |
DisclosureSEC source: 0000899243-20-007281 · doc4.xml · derivative · entry 1 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Ordinary Shares · 36,000 shares Expires 2030-03-03 F1 · derivative.exercise_date: The option vests as to 50% of the shares on February 1, 2021 and 50% on February 1, 2022. Read SEC document |
| March 03, 2020 Filed Mar 6, 2020 01:42 UTC |
BOLNO PAULDirector · President and CEO
|
GrantShare Option (right to buy) · Derivative | 63,000 | $0.00 Strike: $8.17 | $0.00 |
DisclosureSEC source: 0000899243-20-007282 · doc4.xml · derivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,000 Underlying: Ordinary Shares · 63,000 shares Expires 2030-03-03 F1 · derivative.exercise_date: The option vests as to 50% of the shares on February 1, 2021 and 50% on February 1, 2022. Read SEC document |
| March 03, 2020 Filed Mar 6, 2020 01:40 UTC |
Panzara Michael A.Chief Medical Officer
|
GrantShare Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $8.17 | $0.00 |
DisclosureSEC source: 0000899243-20-007277 · doc4.xml · derivative · entry 1 Panzara Michael A. · CIK 0001679039 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Ordinary Shares · 36,000 shares Expires 2030-03-03 F1 · derivative.exercise_date: The option vests as to 50% of the shares on February 1, 2021 and 50% on February 1, 2022 Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:18 UTC |
Vargeese ChandraSenior VP, Drug Discovery
|
SaleOrdinary Shares | 3,188 | $7.85 | $25,025.80 |
DisclosureSEC source: 0000899243-20-005342 · doc4.xml · nonDerivative · entry 1 Vargeese Chandra · CIK 0001657675 · Senior VP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,057 F1 · kind: On February 18, 2020, the reporting person sold 3,188 ordinary shares solely to cover taxes associated with the vesting of restricted share units on February 15, 2020. These sales were made pursuant to a 10b5-1 Trading Plan. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $7.84 to $8.168 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:21 UTC |
Francis ChrisSee Remarks
|
SaleOrdinary Shares | 2,708 | $7.85 | $21,257.80 |
DisclosureSEC source: 0000899243-20-005346 · doc4.xml · nonDerivative · entry 1 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,160 F1 · kind: On February 18, 2020, the reporting person sold 2,708 ordinary shares solely to cover taxes associated with the vesting of restricted share units on February 15, 2020. These sales were made pursuant to a 10b5-1 Trading Plan. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $7.84 to $8.147 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 23:23 UTC |
BOLNO PAULDirector · President and CEO
|
SaleOrdinary Shares | 11,451 | $7.85 | $89,890.35 |
DisclosureSEC source: 0000899243-20-005349 · doc4.xml · nonDerivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,758 F1 · kind: On February 18, 2020, the reporting person sold 11,451 ordinary shares solely to cover taxes associated with the vesting of restricted share units on February 15, 2020. These sales were made pursuant to a 10b5-1 Trading Plan. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $7.84 to $8.148 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 23:26 UTC |
Panzara Michael A.Chief Medical Officer
|
SaleOrdinary Shares | 2,981 | $7.85 | $23,400.85 |
DisclosureSEC source: 0000899243-20-005351 · doc4.xml · nonDerivative · entry 1 Panzara Michael A. · CIK 0001679039 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,349 F1 · kind: On February 18, 2020, the reporting person sold 2,981 ordinary shares solely to cover taxes associated with the vesting of restricted share units on February 15, 2020. These sales were made pursuant to a 10b5-1 Trading Plan. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $7.84 to $8.17 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 18:16 UTC |
Gaiero David GInterim CFO
|
SaleOrdinary Shares | 651 | $7.00 | $4,557.00 |
DisclosureSEC source: 0000899243-20-003379 · doc4.xml · nonDerivative · entry 1 Gaiero David G · CIK 0001799784 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,392 F1 · kind: On February 3, 2020, the reporting person sold 651 ordinary shares solely to cover taxes associated with the vesting of restricted share units on February 1, 2020. These sales were made pursuant to a 10b5-1 Trading Plan. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $7.00 to $7.049 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 18:08 UTC |
Vargeese ChandraSenior VP, Drug Discovery
|
Exercise / conversionShare Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-19-028606 · doc4.xml · derivative · entry 3 Vargeese Chandra · CIK 0001657675 · Senior VP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,542 Underlying: Ordinary Shares · 6,000 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2019. F2 · derivative.exercise_date: The incentive share option initially represented a right to purchase a total of 158,042 ordinary shares, 25% of which became exercisable on August 1, 2015, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 18:08 UTC |
Vargeese ChandraSenior VP, Drug Discovery
|
SaleOrdinary Shares | 6,000 | $35.00 | $210,000.00 |
DisclosureSEC source: 0000899243-19-028606 · doc4.xml · nonDerivative · entry 2 Vargeese Chandra · CIK 0001657675 · Senior VP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,245 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2019. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 18:08 UTC |
Vargeese ChandraSenior VP, Drug Discovery
|
Exercise / conversionOrdinary Shares | 6,000 | $2.48 | $14,880.00 |
DisclosureSEC source: 0000899243-19-028606 · doc4.xml · nonDerivative · entry 1 Vargeese Chandra · CIK 0001657675 · Senior VP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2019. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 17:49 UTC |
Verdine Gregory L.Director
|
SaleOrdinary Shares | 2,609 | $32.74 | $85,418.66 |
DisclosureSEC source: 0000899243-19-027985 · doc4.xml · nonDerivative · entry 3 Verdine Gregory L. · CIK 0001572315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F3 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $32.69 to $32.76 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 17:49 UTC |
Verdine Gregory L.Director
|
SaleOrdinary Shares | 3,400 | $31.59 | $107,406.00 |
DisclosureSEC source: 0000899243-19-027985 · doc4.xml · nonDerivative · entry 2 Verdine Gregory L. · CIK 0001572315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,609 F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $31.50 to $32.04 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 17:49 UTC |
Verdine Gregory L.Director
|
SaleOrdinary Shares | 24,030 | $30.27 | $727,388.10 |
DisclosureSEC source: 0000899243-19-027985 · doc4.xml · nonDerivative · entry 1 Verdine Gregory L. · CIK 0001572315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,009 F1 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $30.07 to $31.045 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 04, 2019 Filed Sep 6, 2019 18:48 UTC |
CORRIGAN MARKDirector
|
GrantShare Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0000899243-19-023038 · doc4.xml · derivative · entry 1 CORRIGAN MARK · CIK 0001250661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Ordinary Shares · 21,000 shares Expires 2024-09-04 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 25% of the shares on September 4, 2020 and the remainder vests quarterly thereafter until September 4, 2023. Read SEC document |
| September 04, 2019 Filed Sep 6, 2019 22:46 UTC |
Wagner Heidi LDirector
|
GrantShare Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0000899243-19-023034 · doc4.xml · derivative · entry 1 Wagner Heidi L · CIK 0001655029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Ordinary Shares · 21,000 shares Expires 2024-09-04 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 25% of the shares on September 4, 2020 and the remainder vests quarterly thereafter until September 4, 2023. Read SEC document |
| September 04, 2019 Filed Sep 6, 2019 22:43 UTC |
Pott AmyDirector
|
GrantShare Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0000899243-19-023032 · doc4.xml · derivative · entry 1 Pott Amy · CIK 0001787363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Ordinary Shares · 21,000 shares Expires 2024-09-04 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 25% of the shares on September 4, 2020 and the remainder vests quarterly thereafter until September 4, 2023. Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 20:21 UTC |
HENRY CHRISTIAN ODirector
|
GrantShare Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $20.34 | $0.00 |
DisclosureSEC source: 0000899243-19-021966 · doc4.xml · derivative · entry 1 HENRY CHRISTIAN O · CIK 0001263805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Ordinary Shares · 10,500 shares Expires 2024-08-15 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2020 annual general meeting or August 15, 2020. Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 20:20 UTC |
Rawcliffe AdrianDirector
|
GrantShare Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $20.34 | $0.00 |
DisclosureSEC source: 0000899243-19-021965 · doc4.xml · derivative · entry 1 Rawcliffe Adrian · CIK 0001555851 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Ordinary Shares · 10,500 shares Expires 2024-08-15 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2020 annual general meeting or August 15, 2020 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.